NCT00651612 - Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients | Biotech Hunter

Enrollment

604

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions

GlaucomaOcular Hypertension

Interventions

DRUG

Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution

Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)

DRUG

Concurrent brimonidine 0.2% and 0.5% timolol

Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)

Trial Locations (1)

Unknown

Newport Beach